机械通气COVID-19 ARDS患者右心室功能与肺血流动力学的全面时序分析
该前瞻性研究对176例机械通气COVID-19 ARDS患者行2D/3D超声心动图全面评估,定义左心室收缩功能障碍为EF<40%或纵向应变(LS)>-18%,右心室功能障碍为FAC<35%、TAPSE<1.6 cm、RV EF<44%、RV-LS>-20%中至少两项。结果显示右心室功能障碍常见(69%),多数患者右心室后负荷增加(PASP 33±1.1 mmHg),LV-LS(-13.3±0.3%)揭示87.5%患者存在沉默性左心室受损。存活者第10个ICU日呼吸生理显著改善,右心室后负荷降低并伴右心室收缩功能改善和右心室扩张消退。第10个ICU日CRS与右心室后负荷和收缩功能相关,第10个ICU日LV-LS、ΔRV-LS和ΔPASP/RVOTVTI与生存相关。
要点
- 机械通气COVID-19 ARDS患者右心室功能障碍常见(69%),常伴右心室扩张(RVEDA/LVEDA 0.82±0.02),多数患者右心室后负荷增加(PASP 33±1.1 mmHg)。
- LV-EF<40%仅占21/176(11.9%),但LV-LS(-13.3±0.3%)揭示87.5%患者存在沉默性左心室受损。
- 存活者第10个ICU日呼吸生理显著改善:PaO2/FiO2 231.2±11.9 vs 120.2±6.7 mmHg,PaCO2 43.1±1.2 vs 53.9±1.5 mmHg,CRS 42.6±2.2 vs 27.8±0.9 ml/cmH2O,均p<0.0001。
- 存活者第10个ICU日右心室后负荷显著降低(PASP 36.1±2.4降至20.1±3 mmHg,p<0.0001;PASP/VTIRVOT 2.5±1.4降至1.1±0.7,p<0.0001;PAcT 61±2.5升至84.7±2.4 ms,p<0.0001),伴右心室收缩功能改善(RVEF 36.5±2.9%升至46.6±2.1%,p=0.001;
- 第10个ICU日CRS与右心室后负荷(PASP/VTIRVOT,r=0.535,p<0.0001)和收缩功能(RV-LS,r=0.345,p=0.001)相关;第10个ICU日LV-LS、ΔRV-LS和ΔPASP/RVOTVTI与生存相关。
适用人群与场景
- 重症COVID-19 ARDS患者,入住ICU并接受机械通气。
- 前瞻性纳入176例患者。
诊断标准与关键阈值
- 左心室收缩功能障碍定义:射血分数(EF)<40%,或纵向应变(LS)>-18%。
- 右心室功能障碍定义:以下指标中至少两项满足:面积变化分数(FAC)<35%、三尖瓣环收缩期位移(TAPSE)<1.6 cm、右心室射血分数(RV EF)<44%、右心室纵向应变(RV-LS)>-20%。
研究设计与关键结果
- 前瞻性研究纳入176例机械通气COVID-19 ARDS患者,行2D/3D超声心动图全面分析。
- 右心室功能障碍常见(69%),平均RV-EF 41.1±1.3%、RV-FAC 36.6±0.9%、TAPSE 20.4±0.4 mm、RV-LS -14.4±0.4%,常伴右心室扩张(RVEDA/LVEDA 0.82±0.02)。
- 多数患者右心室后负荷增加:PASP 33±1.1 mmHg、PAcT 65.3±1.5 ms、PASP/VTIRVOT 2.29±0.1 mmHg/cm;右心室-肺动脉耦联(VACR)为0.8±0.06 mm/mmHg。
- LV-EF<40%见于21/176(11.9%),平均LV-EF 57.8±1.1%;LV-LS(-13.3±0.3%)揭示87.5%患者存在沉默性左心室受损。
- 轻度心包积液见于70例(38%),在非存活者中更常见(p<0.05)。
- 存活者第10个ICU日呼吸生理显著改善:PaO2/FiO2 231.2±11.9 vs 120.2±6.7 mmHg;PaCO2 43.1±1.2 vs 53.9±1.5 mmHg;呼吸系统顺应性(CRS)42.6±2.2 vs 27.8±0.9 ml/cmH2O,均p<0.0001。
- 存活者第10个ICU日右心室后负荷显著降低(PASP 36.1±2.4降至20.1±3 mmHg,p<0.0001;PASP/VTIRVOT 2.5±1.4降至1.1±0.7,p<0.0001;PAcT 61±2.5升至84.7±2.4 ms,p<0.0001),伴右心室收缩功能改善(RVEF 36.5±2.9%升至46.6±2.1%,p=0.001;RV-LS -13.6±0.7%升至-16.7±0.8%,p=0.001)和右心室扩张消退(RVEDA/LVEDA 0.8±0.05降至0.6±0.03,p=0.001)。
- 第10个ICU日CRS与右心室后负荷(PASP/VTIRVOT,r=0.535,p<0.0001)和收缩功能(RV-LS,r=0.345,p=0.001)相关;第10个ICU日LV-LS、ΔRV-LS和ΔPASP/RVOTVTI与生存相关。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对机械通气COVID-19 ARDS患者,应使用2D/3D超声心动图全面评估右心室功能和肺血流动力学,以及时识别常见的右心室功能障碍(69%)和沉默性左心室受损(87.5%)。
- 存活者第10个ICU日右心室功能、后负荷及右心室-肺动脉耦联的改善与呼吸功能改善和生存相关,提示动态监测这些指标可能有助于评估病情转归。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac injury is frequently reported in COVID-19 patients, the right ventricle (RV) is mostly affected. We systematically evaluated the cardiac function and longitudinal changes in severe COVID-19 acute respiratory distress syndrome (ARDS) admitted to the intensive care unit (ICU) and assessed the impact on survival.
METHODS: We prospectively performed comprehensive echocardiographic analysis on mechanically ventilated COVID-19 ARDS patients, using 2D/3D echocardiography. We defined left ventricular (LV) systolic dysfunction as ejection fraction (EF) < 40%, or longitudinal strain (LS) > - 18% and right ventricular (RV) dysfunction if two indices among fractional area change (FAC) < 35%, tricuspid annulus systolic plane excursion (TAPSE) < 1.6 cm, RV EF < 44%, RV-LS > - 20% were present. RV afterload was assessed from pulmonary artery systolic pressure (PASP), PASP/Velocity Time Integral in the right ventricular outflow tract (VTIRVOT) and pulmonary acceleration time (PAcT). TAPSE/PASP assessed the right ventriculoarterial coupling (VACR).
RESULTS: Among 176 patients included, RV dysfunction was common (69%) (RV-EF 41.1 ± 1.3%; RV-FAC 36.6 ± 0.9%, TAPSE 20.4 ± 0.4mm, RV-LS:- 14.4 ± 0.4%), usually accompanied by RV dilatation (RVEDA/LVEDA 0.82 ± 0.02). RV afterload was increased in most of the patients (PASP 33 ± 1.1 mmHg, PAcT 65.3 ± 1.5 ms, PASP/VTIRVOT, 2.29 ± 0.1 mmHg/cm). VACR was 0.8 ± 0.06 mm/mmHg. LV-EF < 40% was present in 21/176 (11.9%); mean LV-EF 57.8 ± 1.1%. LV-LS (- 13.3 ± 0.3%) revealed a silent LV impairment in 87.5%. A mild pericardial effusion was present in 70(38%) patients, more frequently in non-survivors (p < 0.05). Survivors presented significant improvements in respiratory physiology during the 10th ICU-day (PaO2/FiO2, 231.2 ± 11.9 vs 120.2 ± 6.7 mmHg; PaCO2, 43.1 ± 1.2 vs 53.9 ± 1.5 mmHg; respiratory system compliance-CRS, 42.6 ± 2.2 vs 27.8 ± 0.9 ml/cmH2O, all p < 0.0001). Moreover, survivors presented significant decreases in RV afterload (PASP: 36.1 ± 2.4 to 20.1 ± 3 mmHg, p < 0.0001, PASP/VTIRVOT: 2.5 ± 1.4 to 1.1 ± 0.7, p < 0.0001 PAcT: 61 ± 2.5 to 84.7 ± 2.4 ms, p < 0.0001), associated with RV systolic function improvement (RVEF: 36.5 ± 2.9% to 46.6 ± 2.1%, p = 0.001 and RV-LS: - 13.6 ± 0.7% to - 16.7 ± 0.8%, p = 0.001). In addition, RV dilation subsided in survivors (RVEDA/LVEDA: 0.8 ± 0.05 to 0.6 ± 0.03, p = 0.001). Day-10 CRS correlated with RV afterload (PASP/VTIRVOT, r: 0.535, p < 0.0001) and systolic function (RV-LS, 0.345, p = 0.001). LV-LS during the 10th ICU-day, while ΔRV-LS and ΔPASP/RVOTVTI were associated with survival.
CONCLUSIONS: COVID-19 improvements in RV function, RV afterload and RV-PA coupling at day 10 were associated with respiratory function and survival.
参考来源
- Tsolaki V, Zakynthinos GE, Karavidas N, et al. Comprehensive temporal analysis of right ventricular function and pulmonary haemodynamics in mechanically ventilated COVID-19 ARDS patients. Ann Intensive Care. 2024. PMID: 38345712. doi:10.1186/s13613-024-01241-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。